Dencatistat clinical trials
Also written STP938.
How each study uses dencatistat is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the dencatistat studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- STP938
- 3
Studies by the year they started
3 studies that test it; most in 2022 (1)
| Year | Studies |
|---|---|
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 0
Step Pharma, SAS (3)
Related medicines
As reviewed, each with the page that says it.
- One of Antimetabolites source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test dencatistat.
- Dec 2026Study of STP938 (Dencatistat) in Advanced Solid TumoursPhase 1 · Step Pharma, SAS
- Dec 2026A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell LymphomasPhase 1/2 · Step Pharma, SAS
Studies
Open first, then newest update. How each study uses dencatistat is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Study of STP938 (Dencatistat) in Advanced Solid TumoursRecruitingPhase 1Step Pharma, SASNCT06297525Written as STP938
- A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell LymphomasRecruitingPhase 1/2Step Pharma, SASNCT05463263Written as STP938
- A Phase 2 Study to Assess STP938 (Dencatistat) as a Monotherapy in Adults With High Risk Essential Thrombocythaemia - The VECTRA TrialRecruitingPhase 2Step Pharma, SASNCT06786234Written as STP938
Codes
What other systems call dencatistat · ClinicalTrials.gg INT017682
- UNII (FDA) QG9C9SZZ3TDENCATISTATConfirmed FDA, Wikidata
- Wikidata Q140528749dencatistatConfirmed FDA, Wikidata
- NCI Thesaurus C203257DencatistatOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QG9C9SZZ3T | DENCATISTAT | Confirmed FDA, Wikidata |
| Wikidata | Q140528749 | dencatistat | Confirmed FDA, Wikidata |
| NCI Thesaurus | C203257 | Dencatistat | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.